Obesity and its management

Australian Prescriber

Volumn 22, Issue 1, 1999, Pages 12-16

  Caterson, Ian D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Dexfenfluramine; Fat; Fenfluramine; Phentermine

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIOBESITY AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BODY MASS; DIET RESTRICTION; DRUG COST; DRUG EFFICACY; HUMAN; OBESITY; PREVALENCE; REVIEW; RISK FACTOR; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

EID: 0033058122     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.1999.009     Document Type: Review

References (7)

1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: World Health Organization, 1997.
2. McLennan W, Podger A. National Nutrition Survey Selected Highlights Australia 1995. Canberra: Australian Bureau of Statistics and Department of Health and Family Services, 1997.
3. Bouchard C, Tremblay A, Despres JP, Nadeau A, Lupien PJ, Theriault G, et al. The response to long-term overfeeding in identical twins. N Engl J Med 1990;322:1477-82.
4. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
5. Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? Br Med J 1995;311:437-9.
6. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
7. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. Morb Mortal Wkly Rep 1997;46:1061-6.